Company profile: Cellular Research
1.1 - Company Overview
Company description
- Provider of biotechnology R&D and highly sensitive life science technologies, including molecular diagnostics (EasyNAT system and diagnostic kits for pathogens such as SARS-CoV-2, flu, RSV, M. tuberculosis, Mycoplasma pneumoniae), digital PCR for COVID-19 detection and monitoring, cell signalling research services with human cell lines, cell culture media (AffiMEDIUM), and antibodies and antigens (Orbigen).
Products and services
- EasyNAT® SYSTEM: A molecular, fast-screening platform enabling primary diagnosis of pathogens including COVID-19, flu, and RSV, delivering rapid pathogen detection for screening and diagnosis
- EasyNAT Diagnostic Kits: Pathogen-targeted diagnostic assays detecting SARS-CoV-2 variants, M.tuberculosis, Mycoplasma Pneumoniae, and more, supplying detection across multiple pathogens
- Digital PCR in COVID-19 Diagnosis & Monitoring: High-sensitivity method for detecting and monitoring SARS-CoV-2, including mutations and disease progression, offering precise tracking of SARS-CoV-2 mutations and disease progression
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellular Research
Seek Labs
HQ: United States
Website
- Description: Provider of CRISPR-based technology targeting cellular replication to eliminate a cell or pathogen’s ability to replicate, CRISPR-based pharmaceuticals, point-of-care molecular diagnostic tools, laboratory-quality molecular diagnostic testing at the point of care, genetic material purification, and a secure digital platform to communicate easy-to-understand diagnostic results and track health trends.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Seek Labs company profile →
SNIPR Biome
HQ: Denmark
Website
- Description: Provider of CRISPR-based microbial gene therapies that selectively target and eliminate hazardous bacteria without harming beneficial microbes; gut-directed gene therapy via engineered bacteria; CRISPR-Guided Vectors (CGV) for rapid, precise bacterial killing; platforms for in situ therapeutic protein and peptide production; backed by an extensive patent portfolio and research collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SNIPR Biome company profile →
Epimeron
HQ: United States
Website
- Description: Provider of gene discovery, deployment, and optimization solutions that support important plant biochemical functions required for maximum product yield.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Epimeron company profile →
Transgenomic
HQ: United States
Website
- Description: Provider of nucleic acid purification and analysis products for life sciences research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Transgenomic company profile →
Omniome
HQ: United States
Website
- Description: Provider of a proprietary DNA sequencing platform delivering high-accuracy short-read sequencing using Sequencing by Binding (SBB) chemistry. Offers the Onso hardware and software system; validated exome/panel sequencing; single-cell RNA-Seq solutions; and tools for cancer research and gene editing, with lower error rates than traditional sequencing by synthesis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omniome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellular Research
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellular Research
2.2 - Growth funds investing in similar companies to Cellular Research
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellular Research
4.2 - Public trading comparable groups for Cellular Research
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →